ArticleAging cell2026
Chronic Senolytic Treatment and/or Aerobic Exercise Reduce Senescence and Improve Myocardial Function During Aging in the Heart.
Article in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aging is the predominant risk factor for cardiac dysfunction, driven primarily through a decline in cardiomyocyte and overall myocardial performance. Cellular senescence is becoming increasingly linked to its development, as senescent cardiomyocytes and interstitial cells accumulate with age and exhibit persistent DNA damage, mitochondrial dysfunction, and inflammation that collectively impair ventricular relaxation and contractility. Senolytics, which selectively eliminate senescent cells, effectively clear cardiac senescence and its burden, while aerobic exercise has shown promise as a non-pharmacological intervention capable of modulating senescence. Despite this, neither approach has been evaluated as a long-term preventive strategy or whether combining exercise with senolytics produces an additive effect. We hypothesized that when combined, chronic senolytics and aerobic exercise would produce a synergistic clearance of senescent myocardial cells leading to improved cardiac function. Male and female C57BL/6N mice (12-months-old) were randomly allocated to each group and received their intervention for 9-months: naturally aged (VEH, n = 12), aerobic exercise (EX, n = 11), senolytics Dasatinib + Quercetin (D + Q) (SEN, n = 15) or both combined (SENEX, n = 16). Chronic D + Q, exercise, or both, significantly lowered the proportion of p16+, p21+, and γ-H2AX+ cardiomyocytes and interstitial cells, while improving myocardial performance and diastolic function compared to naturally aged mice. At the whole-heart level, protein expression of p16 and p21 increased with age, but was not altered alongside SASP by any intervention. Collectively, these findings demonstrate that long-term exercise or senolytics limit senescence at the cellular level within the myocardium, and improve ventricular function, positioning exercise or senolytics as promising strategies to mitigate age-related cardiac dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.